S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.
J GastroenterolAug 2, 2026 (epub)
Abdulkareem Jomaa, Rani Bshara, Mohammed Alani et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of S1P receptor modulators in adults with moderate-to-severe ulcerative colitis, incorporating data from ten RCTs. The study found that S1P receptor modulators significantly improved clinical remission (RR 2.77; 95% CI, 2.17-3.55) compared to placebo, with moderate to high certainty of evidence.
Key findings
- S1P receptor modulators showed a clinical remission rate of RR 2.77 compared to placebo.
- Clinical response was significantly improved with an RR of 1.69 versus placebo.
- Endoscopic improvement was observed with an RR of 2.29 during induction.
- Serious adverse events were not increased, though treatment-emergent adverse events were modestly higher.
Why it matters
The findings support the use of S1P receptor modulators as effective advanced therapies for moderate-to-severe ulcerative colitis, aligning with current clinical guidelines. Understanding their efficacy can help clinicians make informed treatment decisions.